Kestra Medical Technologies (NASDAQ:KMTS) Insider Timothy Moran Sells 3,192 Shares of Company Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Timothy Moran sold 3,192 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $29.56, for a total value of $94,355.52. Following the completion of the sale, the insider owned 63,153 shares of the company’s stock, valued at $1,866,802.68. This trade represents a 4.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 6.5%

Shares of NASDAQ KMTS traded down $1.97 during mid-day trading on Thursday, reaching $28.53. 730,866 shares of the company’s stock were exchanged, compared to its average volume of 361,929. Kestra Medical Technologies, Ltd. has a twelve month low of $17.34 and a twelve month high of $31.91. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -10.69 and a beta of 0.45. The business has a fifty day simple moving average of $26.86 and a 200 day simple moving average of $23.93.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The business had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. As a group, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kestra Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. lifted its position in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after purchasing an additional 5,731 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after purchasing an additional 22,471 shares during the last quarter. Corient Private Wealth LP grew its position in Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC bought a new position in Kestra Medical Technologies in the first quarter valued at $603,000.

Analyst Ratings Changes

KMTS has been the topic of several research reports. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price objective on the stock. BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Piper Sandler reissued an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Finally, Oppenheimer initiated coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.